Pathological tau drives ectopic nuclear speckle scaffold protein SRRM2 accumulation in neuron cytoplasm in Alzheimer's disease.
- Authors
- McMillan, Pamela J; Strovas, Timothy J; Baum, Misa; Mitchell, Brooke K; Eck, Randall J; Hendricks, Nzinga; Wheeler, Jeanna M; Latimer, Caitlin S; Keene, C Dirk; Kraemer, Brian C
- Year
- 2021
- Journal
- Acta neuropathologica communications
- PMID
- 34187600
- DOI
- 10.1186/s40478-021-01219-1
- PMCID
- PMC8243890
Several conserved nuclear RNA binding proteins (sut-1, sut-2, and parn-2) control tau aggregation and toxicity in C. elegans, mice, and human cells. MSUT2 protein normally resides in nuclear speckles, membraneless organelles composed of phase-separated RNAs and RNA-binding proteins that mediate critical steps in mRNA processing including mRNA splicing. We used human pathological tissue and transgenic mice to identify Alzheimer's disease-specific cellular changes related to nuclear speckles. We observed that nuclear speckle constituent scaffold protein SRRM2 is mislocalized and accumulates in cytoplasmic lesions in AD brain tissue. Furthermore, progression of tauopathy in transgenic mice is accompanied by increasing mislocalization of SRRM2 from the neuronal nucleus to the soma. In AD brain tissue, SRRM2 mislocalization associates with increased severity of pathological tau deposition. These findings suggest potential mechanisms by which pathological tau impacts nuclear speckle function in diverse organisms ranging from C. elegans to mice to humans. Future translational studies aimed at restoring nuclear speckle homeostasis may provide novel candidate therapeutic targets for pharmacological intervention.
Derangement of nuclear speckle marker pSRRM2 (ab SC-35) in AD. Immunohistochemistry using a pSRRM2 recognizing antibody raised against purified human spliceosomes (clone SC-35, see Table 2). Human pSRRM2 stains nuclear speckles within neurons in the frontal cortex of the normal adult human brain (a). A subset of AD donors (30%) also exhibit normal nuclear speckle staining in cortical neurons (b), however, the majority of AD donors (72%) exhibit striking mis-localization of pSRRM2 to the cytoplasm in neurons in the frontal cortex (c). Additionally, all AD donors exhibited mis-localization of pSRRM2 in the hippocampus (d) and amygdala (e), brain regions where tauopathy occurs earlier in disease progression. AD donors with aberrant cytoplasmic pSRRM2 in tauopathy rich regions showed normal nuclear pSRRM2 distribution in cerebellar neurons (f), which do not typically exhibit any tau pathology. Scale bars, 50 µm
Abnormal pSRRM2 mis-localization occurs in a transgenic mouse model of tauopathy. Immunostaining with SC-35 antibody (a, c, e, g) demonstrates that pSRRM2 is mis-localized to the neuronal cytoplasm in brain regions of PS19 mice where Gallyas positive NFTs (b, d, f) are prevalent. At three months, pSRRM2 appears as diffuse mild immunoreactivity in the cytoplasm (a) and there are no tangles (b). At seven months, a small number of Gallyas positive NFTs are present and neurons with robust cytoplasmic distribution are detectable in these same regions (c, d). By nine months, PS19 mice with robust tangle burden display abnormal pSRRM2 cytoplasmic localization in a large number of neurons (e, f and quantified in h). In contrast, pSRRM2 is not detectable in a nine-month-old non-Tg mouse brain (g). (*p = 0.04 by two-tailed Student’s t test) Scale bars, 100 µm
pSRRM2 co-localizes with pathological tau in AD. a pSRRM2 (Red) is localized to the nucleus and pTau (pS422-Green) is cytoplasmic in cognitively normal elderly controls; visible overlapping signal is visualized as yellow (Pearson Coefficient of Colocalization = 0.017), (Panel image scale bar = 100um; inset scale bar = 25um). b pSRRM2 (Red) relocalizes to the cytoplasm and colocalizes with pTau (Green), as visualized in yellow in AD patients (Pearson Coefficient of Colocalization = 0.99). (Panel image scale bar = 100um; inset scale bar = 10um). c Proximity Ligation Assay imaging between pSRRM2 and pTau. Top: Panel image and inset imaging of PLA colocalization in a cognitively normal elderly control donor shows minimal cytoplasmic colocalization (Panel image scale bar = 100um; inset scale bar = 10um). Bottom: Panel image and inset imaging of PLA colocalization in an AD donor show significant colocalization in the cytoplasm (Panel image scale bar = 100um; inset scale bar = 10um)
pSRRM2 mis-localization in AD associates with disease severity. Cytoplasmic pSRRM2 accumulation in AD brain is associated with a more aggressive disease progression. a AD donors with predominately cytoplasmic pSRRM2 in postmortem frontal cortex (n = 20) had an earlier age of disease onset compared to those with primarily nuclear pSRRM2 distribution (n = 9) (**p = 0.0042 by two-tailed Student’s t test). b Representative brain sections from frontal cortex of an AD donor with normal nuclear pSRRM2 distribution (top) compared to an AD donor with abnormal cytoplasmic accumulation of pSRRM2 (bottom) stained with the anti-phosphorylated tau antibody AT180. Brain tissue from cases with cytoplasmic pSRRM2 exhibited more pathological tau. Densitometry analysis of AT180-positive reactivity in AD cases with nuclear (n = 8) or cytoplasmic (n = 19) pSRRM2 (***p = 0.0002 by two-tailed Student’s t test). c Representative brain sections from postmortem brain frontal cortex of an AD donor with normal nuclear pSRRM2 distribution (top) compared to an AD donor with abnormal cytoplasmic accumulation of pSRRM2 (bottom) stained with the neuronal marker NeuN. Brain tissue from cases with cytoplasmic pSRRM2 exhibited decreased NeuN immunoreactivity (indicative of more neuronal loss). Densitometry analysis of NeuN-positive reactivity in AD cases with nuclear (n = 9) or cytoplasmic (n = 18) pSRRM2 (**p = 0.0025 by two-tailed Student’s t test). Scale bars, 250 µm
Nuclear Speckle disruption occurs as a result of pathological tau in AD. a Changes associated with aging, including decreased proteostasis, increased neuroinflammation, and metabolic challenge, contribute to the initiation of amyloid plaque deposition. Plaques have been shown to trigger a tauopathy cascade. Here we demonstrate that pathological tau deposition coincides with depletion of nuclear speckle scaffold protein SRRM2 from the nucleus. Nuclear SRRM2 function within nuclear speckles is required for appropriate mRNA processing. Inefficient mRNA processing causes neurodegeneration. b Phosphorylation of SRRM2 at pS1068 drives SRRM2 transit from the nucleus to cytoplasm and we propose that pathological tau provokes phosphorylation and mislocalization of SRRM2 through an ER stress and ERK1/2 mediated pathway which leads to neurodegeneration. c Modulation of nuclear speckle content via loss of regulatory RNA binding proteins resident in nuclear speckles such as SUT-1 or SUT-2/MSUT2 can fully rescue tauopathy phenotypes. We propose that the sut RNA binding protein pathway modulates tauopathy by restoring nuclear speckle function in the face of pathological tau
No entities extracted from this document yet.
No uploaded files.
In this knowledge base
| Title | Year | PMID |
|---|---|---|
| RNA alternative splicing impacts the risk for alcohol use disorder. | 2023 | 37217680 |
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Localisation and organisation of the focal adhesion kinase FAK1 and Simiate inside nuclear speckles. | Dahlhaus R et al. | — | 2026 | → |
| Polyserine domains are toxic and exacerbate tau pathology in mice. | Van Alstyne M et al. | — | 2026 | → |
| Proximity Labeling of the Tau Repeat Domain Enriches RNA-Binding Proteins That Are Altered in Alzheimer's Disease and Related Tauopathies. | Shapley SM et al. | — | 2026 | → |
| Biomolecular condensates: molecular structure, biological functions, diseases, and therapeutic targets. | Choi S et al. | — | 2025 | → |
| Cajal's organization of neuronal nucleus revisited. | Lafarga M et al. | — | 2025 | → |
| Diverse influences on tau aggregation and implications for disease progression. | Van Alstyne M et al. | — | 2025 | → |
| Nuclear ribonucleoprotein condensates as platforms for gene expression regulation. | Choi S et al. | — | 2025 | → |
| Nuclear Tau accumulation in Alzheimer's disease. | Chinnathambi S et al. | — | 2025 | → |
| Pathogenic oligomeric Tau alters neuronal RNA processes through the formation of nuclear heteromeric amyloids with RNA-binding protein Musashi1. | Puangmalai N et al. | — | 2025 | → |
| Pharmacological interventions on GSK3β phosphorylation-mediated tau aggregation by modulating phase separation of tau proline-rich domain. | Sun S et al. | — | 2025 | → |
| Polyserine-mediated targeting of FAF2/UBXD8 ameliorates tau aggregation. | Van Alstyne M et al. | — | 2025 | → |
| Polyserine-tau interactions modulate tau fibrillization. | Pratt J et al. | — | 2025 | → |
| Spliceosome protein alterations differentiate hubs of the default mode connectome during the progression of Alzheimer's disease. | Perez SE et al. | — | 2025 | → |
| The splicing factor SRRM2 modulates two S6K kinases to promote colorectal cancer growth. | Yan Z et al. | — | 2025 | → |
| TMEM106B C-terminal fragments aggregate and drive neurodegenerative proteinopathy in transgenic Caenorhabditis elegans. | Riordan R et al. | — | 2025 | → |
| A single-cell and spatial RNA-seq database for Alzheimer's disease (ssREAD). | Wang C et al. | — | 2024 | → |
| Disruption of nuclear speckle integrity dysregulates RNA splicing in C9ORF72-FTD/ALS. | Wu R et al. | — | 2024 | → |
| Polyserine peptides are toxic and exacerbate tau pathology in mice | Van Alstyne M et al. | — | 2024 | — |
| Single-nucleus transcriptomic profiling of human orbitofrontal cortex reveals convergent effects of aging and psychiatric disease. | Fröhlich AS et al. | — | 2024 | → |
| SRRM2 may be a potential biomarker and immunotherapy target for multiple myeloma: a real-world study based on flow cytometry detection. | Guo J et al. | — | 2024 | → |
| Tau, RNA, and RNA-Binding Proteins: Complex Interactions in Health and Neurodegenerative Diseases. | Lester E et al. | — | 2024 | → |
| The Nuclear Speckles Protein SRRM2 Is Exposed on the Surface of Cancer Cells. | Kellner M et al. | — | 2024 | → |
| The RNA-binding protein Nab2 regulates levels of the RhoGEF Trio to govern axon and dendrite morphology. | Lancaster CL et al. | — | 2024 | → |
| The role of microRNAs in understanding sex-based differences in Alzheimer's disease. | Llera-Oyola J et al. | — | 2024 | → |
| All the Tau We Cannot See. | Hyman B | — | 2023 | → |
| Cytosolic condensates rich in polyserine define subcellular sites of tau aggregation. | Lester E et al. | — | 2023 | → |
| Familial and genetic association with neurodevelopmental disorders caused by a heterozygous variant in the <i>SRRM2</i> gene. | Zhang T et al. | — | 2023 | → |
| Formation, function, and pathology of RNP granules. | Ripin N et al. | — | 2023 | → |
| Nuclear face of Tau: an inside player in neurodegeneration. | Younas N et al. | — | 2023 | → |
| Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer's disease and primary tauopathies. | Hart de Ruyter FJ et al. | — | 2023 | → |
| RNA alternative splicing impacts the risk for alcohol use disorder. | Li R et al. | — | 2023 | → |
| Schizophrenia risk conferred by rare protein-truncating variants is conserved across diverse human populations. | Liu D et al. | — | 2023 | → |
| SPOP loss of function protects against tauopathy. | Eck RJ et al. | — | 2023 | → |
| Sut-6/NIPP1 modulates tau toxicity. | Kow RL et al. | — | 2023 | → |
| Tau-RNA complexes inhibit microtubule polymerization and drive disease-relevant conformation change. | McMillan PJ et al. | — | 2023 | → |
| The Proteome Profile of Olfactory Ecto-Mesenchymal Stem Cells-Derived from Patients with Familial Alzheimer's Disease Reveals New Insights for AD Study. | Rochín-Hernández LJ et al. | — | 2023 | → |
| Disruption of nuclear envelope integrity as a possible initiating event in tauopathies. | Prissette M et al. | — | 2022 | → |
| Keeping up with the condensates: The retention, gain, and loss of nuclear membrane-less organelles. | Lacroix E et al. | — | 2022 | → |
| Loss of aly/ALYREF suppresses toxicity in both tau and TDP-43 models of neurodegeneration. | Kow RL et al. | — | 2022 | → |
| Nuclear-Import Receptors Counter Deleterious Phase Transitions in Neurodegenerative Disease. | Odeh HM et al. | — | 2022 | → |
| Nuclear speckles - a driving force in gene expression. | Faber GP et al. | — | 2022 | → |
| Single Nucleus Transcriptome Data from Alzheimer's Disease Mouse Models Yield New Insight into Pathophysiology. | Weller AE et al. | — | 2022 | → |
| TDP-43 promotes tau accumulation and selective neurotoxicity in bigenic Caenorhabditis elegans. | Latimer CS et al. | — | 2022 | → |